US › Healthcare

Vivos Therapeutics Inc (VVOS)

US · Healthcare · Medical Devices

$0.13-8.19%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$5.2M

Revenue YoY

+34.9%

Net profit

$-5.5M

EPS

$-0.31

EPS estimate

$-0.42

Net margin

-106.4%

EPS came in at -0.31 against a street estimate of -0.42 — a beat of 26.2%.

Key statistics

Market cap

$5.0M

Forward P/E

0.0

P/B

6.86

Book value

$-0.34

EPS (TTM)

$-1.88

52-week high

$3.28

52-week low

$0.13

50-day MA

$0.23

200-day MA

$0.89

Beta

6.07

Analyst view

Analysts rate Vivos Therapeutics Inc a buy (2 buy, 1 hold, 0 sell out of 3) with an average price target of $2.12.

Shareholding

Insiders

11.32%

Institutions

3.90%

Largest institutional holders

Fund	Stake
Geode Capital Management, LLC	0.25%
IHT Wealth Management, LLC	0.23%
Vanguard Capital Management, LLC	0.18%
Commonwealth Equity Services, LLC	0.13%
UBS Group AG	0.12%
National Asset Management Inc	0.11%
Centurion Wealth Management LLC	0.11%
BlackRock Inc	0.08%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Vivos Therapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.